XML 39 R2.htm IDEA: XBRL DOCUMENT v3.8.0.1
Consolidated Balance Sheets - USD ($)
$ in Thousands
Dec. 29, 2017
Dec. 30, 2016
Current assets:    
Cash and cash equivalents $ 183,164 $ 151,686
Short-term investments 204,607 268,117
Short-term restricted cash and investments 504 0
Trade and other receivables, net 81,192 40,444
Inventory, net 6,657 3,338
Prepaid expenses and other current assets 8,750 5,416
Total current assets 484,874 469,001
Long-term investments 64,255 55,601
Long-term restricted cash and investments 4,646 4,150
Property and equipment, net 25,743 2,071
Goodwill 63,684 63,684
Other long-term assets 12,092 1,232
Total assets 655,294 595,739
Current liabilities:    
Accounts payable 9,575 6,565
Accrued compensation and benefits 21,073 20,334
Accrued clinical trial liabilities 19,849 14,131
Accrued collaboration liabilities 8,974 2,046
Rebates and fees due to customers 7,565 3,420
Current portion of deferred revenue 31,984 19,665
Convertible notes 0 109,122
Term loan payable 0 80,000
Other current liabilities 16,150 13,503
Total current liabilities 115,170 268,786
Long-term portion of deferred revenue 238,520 237,094
Other long-term liabilities 16,643 541
Total liabilities 370,333 506,421
Commitments (Note 12)
Stockholders’ equity:    
Preferred stock, $0.001 par value, 10,000,000 shares authorized and no shares issued 0 0
Common stock, $0.001 par value; 400,000,000 shares authorized; issued and outstanding: 296,209,426 and 289,923,798 at December 31, 2017 and 2016, respectively 296 290
Additional paid-in capital 2,114,184 2,072,591
Accumulated other comprehensive loss (347) (416)
Accumulated deficit (1,829,172) (1,983,147)
Total stockholders’ equity 284,961 89,318
Total liabilities and stockholders’ equity $ 655,294 $ 595,739